Perhaps no other recent topic in oncology has generated as much excitement as the immunotherapies. PD-1s, checkpoint inhibitors, CAR-T, and DC therapies – all have become common fare for those following cancer drug development. Indeed, “Cancer Immunotherapy” was voted the Science Breakthrough of the Year for 2013 (Science, Vol. 342, no. 6165) and MD Anderson promoted immunotherapies as part of their ambitious Moon Shots program. And attendees at the recent 2014 American Association for Cancer Research witnessed a flood of immunotherapy sessions first-hand.

This report focuses on the promising new classes of therapies that have driven a renewed interest in the field. Topics covered include:

• Programmed-death (anti-PD-1 drugs) and other immune checkpoint inhibitors
• Dendritic cell (DC) therapies
• T-cell therapies (CAR-T)
• Cancer vaccines

For the full report, please download the PDF version at the top of this page.

For our disclosures, please read the BioMedTracker Research Standards.